{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:28:10Z","timestamp":1788323290736,"version":"build-2803163510"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,17]]},"DOI":"10.7759\/cureus.25076","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T14:55:18Z","timestamp":1652799318000},"source":"Crossref","is-referenced-by-count":38,"title":["Cardio-Metabolic Disease and Polycystic Ovarian Syndrome (PCOS): A Narrative Review"],"prefix":"10.7759","author":[{"given":"Sai Lahari","family":"Sangaraju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Yepez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier  A","family":"Grandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Talanki Manjunatha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2015.12.013","article-title":"Stein and Leventhal: 80 years on","volume":"214","author":"Azziz R","year":"2016","unstructured":"Azziz R, Adashi EY. Stein and Leventhal: 80 years on. Am J Obstet Gynecol. 2016, 214:247. 10.1016\/j.ajog.2015.12.013","journal-title":"Am J Obstet Gynecol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dew218","article-title":"The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis","volume":"31","author":"Bozdag G","year":"2016","unstructured":"Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016, 31:2841-55. 10.1093\/humrep\/dew218","journal-title":"Hum Reprod"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2003.10.004","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome","volume":"81","author":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group","year":"2004","unstructured":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004, 81:19-25. 10.1016\/j.fertnstert.2003.10.004","journal-title":"Fertil Steril"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2016.05.003","article-title":"Criteria, prevalence, and phenotypes of polycystic ovary syndrome","volume":"106","author":"Lizneva D","year":"2016","unstructured":"Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016, 106:6-15. 10.1016\/j.fertnstert.2016.05.003","journal-title":"Fertil Steril"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1327","article-title":"Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features","volume":"91","author":"Welt CK","year":"2006","unstructured":"Welt CK, Gudmundsson JA, Arason G, et al.. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab. 2006, 91:4842-8. 10.1210\/jc.2006-1327","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmp008","article-title":"Metabolic features of the reproductive phenotypes of polycystic ovary syndrome","volume":"15","author":"Moran L","year":"2009","unstructured":"Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update. 2009, 15:477-88. 10.1093\/humupd\/dmp008","journal-title":"Hum Reprod Update"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-015-3889-5","article-title":"Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria","volume":"293","author":"Jamil AS","year":"2016","unstructured":"Jamil AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T. Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria. Arch Gynecol Obstet. 2016, 293:447-56. 10.1007\/s00404-015-3889-5","journal-title":"Arch Gynecol Obstet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjtm.2015.07.001","article-title":"Risk factors of polycystic ovarian syndrome among Li people","volume":"8","author":"Shan B","year":"2015","unstructured":"Shan B, Cai JH, Yang SY, Li ZR. Risk factors of polycystic ovarian syndrome among Li people. Asian Pac J Trop Med. 2015, 8:590-3. 10.1016\/j.apjtm.2015.07.001","journal-title":"Asian Pac J Trop Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1385\/ENDO:30:1:19","article-title":"The role of genes and environment in the etiology of PCOS","volume":"30","author":"Diamanti-Kandarakis E","year":"2006","unstructured":"Diamanti-Kandarakis E, Kandarakis H, Legro RS. The role of genes and environment in the etiology of PCOS. Endocrine. 2006, 30:19-26. 10.1385\/ENDO:30:1:19","journal-title":"Endocrine"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1542-2011.2012.00161.x","article-title":"Polycystic ovary syndrome: a common but often unrecognized condition","volume":"57","author":"Shannon M","year":"2012","unstructured":"Shannon M, Wang Y. Polycystic ovary syndrome: a common but often unrecognized condition. J Midwifery Womens Health. 2012, 57:221-30. 10.1111\/j.1542-2011.2012.00161.x","journal-title":"J Midwifery Womens Health"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2010.217","article-title":"Polycystic ovary syndrome: etiology, pathogenesis and diagnosis","volume":"7","author":"Goodarzi MO","year":"2011","unstructured":"Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011, 7:219-31. 10.1038\/nrendo.2010.217","journal-title":"Nat Rev Endocrinol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-017-1047-7","article-title":"Polycystic ovary syndrome throughout a woman's life","volume":"35","author":"Bellver J","year":"2018","unstructured":"Bellver J, Rodr\u00edguez-Tabernero L, Robles A, et al.. Polycystic ovary syndrome throughout a woman's life. J Assist Reprod Genet. 2018, 35:25-39. 10.1007\/s10815-017-1047-7","journal-title":"J Assist Reprod Genet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2012.10.029","article-title":"Longterm management of polycystic ovarian syndrome (PCOS)","volume":"373","author":"Bates GW","year":"2013","unstructured":"Bates GW, Legro RS. Longterm management of polycystic ovarian syndrome (PCOS). Mol Cell Endocrinol. 2013, 373:91-7. 10.1016\/j.mce.2012.10.029","journal-title":"Mol Cell Endocrinol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/2633494120911038","article-title":"Characteristics of polycystic ovary syndrome throughout life","volume":"14","author":"Louwers YV","year":"2020","unstructured":"Louwers YV, Laven JSE. Characteristics of polycystic ovary syndrome throughout life. Ther Adv Reprod Health. 2020, 14:2633494120911038. 10.1177\/2633494120911038","journal-title":"Ther Adv Reprod Health"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1210\/er.2012-1003","article-title":"Cardiometabolic aspects of the polycystic ovary syndrome","volume":"33","author":"Randeva HS","year":"2012","unstructured":"Randeva HS, Tan BK, Weickert MO, Lois K, Nestler JE, Sattar N, Lehnert H. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev. 2012, 33:812-41. 10.1210\/er.2012-1003","journal-title":"Endocr Rev"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.18.6.0318","article-title":"Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis","volume":"18","author":"Dunaif A","year":"1997","unstructured":"Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997, 18:774-800. 10.1210\/edrv.18.6.0318","journal-title":"Endocr Rev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c110062","article-title":"Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training","volume":"3","author":"Roberts CK","year":"2013","unstructured":"Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol. 2013, 3:1-58. 10.1002\/cphy.c110062","journal-title":"Compr Physiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2017.09.016","article-title":"Polycystic ovarian syndrome (PCOS): long-term metabolic consequences","volume":"86","author":"Anagnostis P","year":"2018","unstructured":"Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): long-term metabolic consequences. Metabolism. 2018, 86:33-43. 10.1016\/j.metabol.2017.09.016","journal-title":"Metabolism"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/s0015-0282(02)03111-4","article-title":"Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus","volume":"77","author":"Ovalle F","year":"2002","unstructured":"Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril. 2002, 77:1095-105. 10.1016\/s0015-0282(02)03111-4","journal-title":"Fertil Steril"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.1.5393","article-title":"Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women","volume":"84","author":"Legro RS","year":"1999","unstructured":"Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999, 84:165-9. 10.1210\/jcem.84.1.5393","journal-title":"J Clin Endocrinol Metab"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.685628","article-title":"Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab)","volume":"116","author":"Barr EL","year":"2007","unstructured":"Barr EL, Zimmet PZ, Welborn TA, et al.. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation. 2007, 116:151-7. 10.1161\/CIRCULATIONAHA.106.685628","journal-title":"Circulation"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/16.9.1995","article-title":"Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome","volume":"16","author":"Norman RJ","year":"2001","unstructured":"Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod. 2001, 16:1995-8. 10.1093\/humrep\/16.9.1995","journal-title":"Hum Reprod"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2007.02157.x","article-title":"International Diabetes Federation: a consensus on type 2 diabetes prevention","volume":"24","author":"Alberti KG","year":"2007","unstructured":"Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabet Med. 2007, 24:451-63. 10.1111\/j.1464-5491.2007.02157.x","journal-title":"Diabet Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"Alberti KGMM","year":"2009","unstructured":"Alberti KGMM, Eckel RH, Grundy SM, et al.. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009, 120:1640-5. 10.1161\/CIRCULATIONAHA.109.192644","journal-title":"Circulation"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/GRF.0b013e31802f3547","article-title":"The metabolic syndrome in polycystic ovary syndrome","volume":"50","author":"Essah PA","year":"2007","unstructured":"Essah PA, Wickham EP, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. Clin Obstet Gynecol. 2007, 50:205-25. 10.1097\/GRF.0b013e31802f3547","journal-title":"Clin Obstet Gynecol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12762","article-title":"Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression","volume":"20","author":"Lim SS","year":"2019","unstructured":"Lim SS, Kakoly NS, Tan JW, et al.. Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Obes Rev. 2019, 20:339-52. 10.1111\/obr.12762","journal-title":"Obes Rev"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmq001","article-title":"Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis","volume":"16","author":"Moran LJ","year":"2010","unstructured":"Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010, 16:347-63. 10.1093\/humupd\/dmq001","journal-title":"Hum Reprod Update"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1666","article-title":"Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance","volume":"91","author":"Coviello AD","year":"2006","unstructured":"Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2006, 91:492-7. 10.1210\/jc.2005-1666","journal-title":"J Clin Endocrinol Metab"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a115424","article-title":"Relation of body fatness and its distribution to cardiovascular risk factors in young blacks and whites. The role of insulin","volume":"130","author":"Folsom AR","year":"1989","unstructured":"Folsom AR, Burke GL, Ballew C, et al.. Relation of body fatness and its distribution to cardiovascular risk factors in young blacks and whites. The role of insulin. Am J Epidemiol. 1989, 130:911-24. 10.1093\/oxfordjournals.aje.a115424","journal-title":"Am J Epidemiol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2010.12.027","article-title":"Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis","volume":"95","author":"Wild RA","year":"2011","unstructured":"Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril. 2011, 95:1073-9. 10.1016\/j.fertnstert.2010.12.027","journal-title":"Fertil Steril"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2007.07.004","article-title":"Pathophysiology and types of dyslipidemia in PCOS","volume":"18","author":"Diamanti-Kandarakis E","year":"2007","unstructured":"Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab. 2007, 18:280-5. 10.1016\/j.tem.2007.07.004","journal-title":"Trends Endocrinol Metab"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31820209bb","article-title":"Polycystic ovary syndrome and risk for long-term diabetes and dyslipidemia","volume":"117","author":"Wang ET","year":"2011","unstructured":"Wang ET, Calderon-Margalit R, Cedars MI, et al.. Polycystic ovary syndrome and risk for long-term diabetes and dyslipidemia. Obstet Gynecol. 2011, 117:6-13. 10.1097\/AOG.0b013e31820209bb","journal-title":"Obstet Gynecol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dms030","article-title":"Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis","volume":"18","author":"Lim SS","year":"2012","unstructured":"Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012, 18:618-37. 10.1093\/humupd\/dms030","journal-title":"Hum Reprod Update"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1089\/obe.2007.0019","article-title":"Obesity and polycystic ovary syndrome","volume":"3","author":"Sam S","year":"2007","unstructured":"Sam S. Obesity and polycystic ovary syndrome. Obes Manag. 2007, 3:69-73. 10.1089\/obe.2007.0019","journal-title":"Obes Manag"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.19.2081","article-title":"Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women","volume":"166","author":"Alvarez-Blasco F","year":"2006","unstructured":"Alvarez-Blasco F, Botella-Carretero JI, San Mill\u00e1n JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med. 2006, 166:2081-6. 10.1001\/archinte.166.19.2081","journal-title":"Arch Intern Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.humrep.a136243","article-title":"Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients","volume":"10","author":"Balen AH","year":"1995","unstructured":"Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C, Jacobs HS. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod. 1995, 10:2107-11. 10.1093\/oxfordjournals.humrep.a136243","journal-title":"Hum Reprod"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/ng.732","article-title":"Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3","volume":"43","author":"Chen ZJ","year":"2011","unstructured":"Chen ZJ, Zhao H, He L, et al.. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet. 2011, 43:55-9. 10.1038\/ng.732","journal-title":"Nat Genet"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2018.11.001","article-title":"Does body weight affect cardiometabolic risk in women with polycystic ovary syndrome?","volume":"111","author":"Dokras A","year":"2019","unstructured":"Dokras A. Does body weight affect cardiometabolic risk in women with polycystic ovary syndrome?. Fertil Steril. 2019, 111:56-7. 10.1016\/j.fertnstert.2018.11.001","journal-title":"Fertil Steril"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2018.11.034","article-title":"ACC\/AHA 2017 definition of high blood pressure: implications for women with polycystic ovary syndrome","volume":"111","author":"Marchesan LB","year":"2019","unstructured":"Marchesan LB, Spritzer PM. ACC\/AHA 2017 definition of high blood pressure: implications for women with polycystic ovary syndrome. Fertil Steril. 2019, 111:579-87. 10.1016\/j.fertnstert.2018.11.034","journal-title":"Fertil Steril"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0399","article-title":"Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome","volume":"91","author":"Cascella T","year":"2006","unstructured":"Cascella T, Palomba S, Tauchmanov\u00e0 L, et al.. Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2006, 91:4395-400. 10.1210\/jc.2006-0399","journal-title":"J Clin Endocrinol Metab"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137609","article-title":"Trend of cardio-metabolic risk factors in polycystic ovary syndrome: a population-based prospective cohort study","volume":"10","author":"Ramezani Tehrani F","year":"2015","unstructured":"Ramezani Tehrani F, Montazeri SA, Hosseinpanah F, Cheraghi L, Erfani H, Tohidi M, Azizi F. Trend of cardio-metabolic risk factors in polycystic ovary syndrome: a population-based prospective cohort study. PLoS One. 2015, 10:e0137609. 10.1371\/journal.pone.0137609","journal-title":"PLoS One"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13497","article-title":"Women with polycystic ovary syndrome demonstrate worsening markers of cardiovascular risk over the short-term despite declining hyperandrogenaemia: results of a longitudinal study with community controls","volume":"87","author":"Huddleston HG","year":"2017","unstructured":"Huddleston HG, Quinn MM, Kao CN, Lenhart N, Rosen MP, Cedars MI. Women with polycystic ovary syndrome demonstrate worsening markers of cardiovascular risk over the short-term despite declining hyperandrogenaemia: results of a longitudinal study with community controls. Clin Endocrinol. 2017, 87:775-82. 10.1111\/cen.13497","journal-title":"Clin Endocrinol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031867","article-title":"Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome","volume":"89","author":"Orio F Jr","year":"2004","unstructured":"Orio F Jr, Palomba S, Cascella T, et al.. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004, 89:4588-93. 10.1210\/jc.2003-031867","journal-title":"J Clin Endocrinol Metab"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0011","article-title":"Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease","volume":"90","author":"Meyer C","year":"2005","unstructured":"Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab. 2005, 90:5711-6. 10.1210\/jc.2005-0011","journal-title":"J Clin Endocrinol Metab"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1487","article-title":"Vascular dysfunction and metabolic parameters in polycystic ovary syndrome","volume":"90","author":"Meyer C","year":"2005","unstructured":"Meyer C, McGrath BP, Cameron J, Kotsopoulos D, Teede HJ. Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. J Clin Endocrinol Metab. 2005, 90:4630-5. 10.1210\/jc.2004-1487","journal-title":"J Clin Endocrinol Metab"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-032237","article-title":"Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome","volume":"89","author":"Talbott EO","year":"2004","unstructured":"Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004, 89:5454-61. 10.1210\/jc.2003-032237","journal-title":"J Clin Endocrinol Metab"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-1-199701010-00005","article-title":"Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization","volume":"126","author":"Birdsall MA","year":"1997","unstructured":"Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med. 1997, 126:32-5. 10.7326\/0003-4819-126-1-199701010-00005","journal-title":"Ann Intern Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-10-103","article-title":"Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes","volume":"10","author":"Yoo HJ","year":"2011","unstructured":"Yoo HJ, Hwang SY, Hong HC, et al.. Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovasc Diabetol. 2011, 10:103. 10.1186\/1475-2840-10-103","journal-title":"Cardiovasc Diabetol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19180","article-title":"The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis","volume":"8","author":"Ding T","year":"2017","unstructured":"Ding T, Hardiman PJ, Petersen I, Wang FF, Qu F, Baio G. The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis. Oncotarget. 2017, 8:96351-8. 10.18632\/oncotarget.19180","journal-title":"Oncotarget"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2017.1347779","article-title":"Association between polycystic ovary syndrome and the risk of stroke and all-cause mortality: insights from a meta-analysis","volume":"33","author":"Zhou Y","year":"2017","unstructured":"Zhou Y, Wang X, Jiang Y, et al.. Association between polycystic ovary syndrome and the risk of stroke and all-cause mortality: insights from a meta-analysis. Gynecol Endocrinol. 2017, 33:904-10. 10.1080\/09513590.2017.1347779","journal-title":"Gynecol Endocrinol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.628875","article-title":"Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis","volume":"115","author":"Lorenz MW","year":"2007","unstructured":"Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007, 115:459-67. 10.1161\/CIRCULATIONAHA.106.628875","journal-title":"Circulation"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9553","article-title":"Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis","volume":"7","author":"Zhao L","year":"2016","unstructured":"Zhao L, Zhu Z, Lou H, Zhu G, Huang W, Zhang S, Liu F. Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis. Oncotarget. 2016, 7:33715-21. 10.18632\/oncotarget.9553","journal-title":"Oncotarget"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1995.tb00534.x","article-title":"Cardiac flow velocity in women with the polycystic ovary syndrome","volume":"43","author":"Prelevic GM","year":"1995","unstructured":"Prelevic GM, Beljic T, Balint-Peric L, Ginsburg J. Cardiac flow velocity in women with the polycystic ovary syndrome. Clin Endocrinol. 1995, 43:677-81. 10.1111\/j.1365-2265.1995.tb00534.x","journal-title":"Clin Endocrinol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-032049","article-title":"The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study","volume":"89","author":"Orio F Jr","year":"2004","unstructured":"Orio F Jr, Palomba S, Spinelli L, et al.. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab. 2004, 89:3696-701. 10.1210\/jc.2003-032049","journal-title":"J Clin Endocrinol Metab"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/s0015-0282(01)01937-9","article-title":"Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome","volume":"76","author":"Yarali H","year":"2001","unstructured":"Yarali H, Yildirir A, Aybar F, et al.. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril. 2001, 76:511-6. 10.1016\/s0015-0282(01)01937-9","journal-title":"Fertil Steril"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0680-5","article-title":"Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome","volume":"17","author":"Glintborg D","year":"2018","unstructured":"Glintborg D, Rubin KH, Nybo M, Abrahamsen B, Andersen M. Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome. Cardiovasc Diabetol. 2018, 17:37. 10.1186\/s12933-018-0680-5","journal-title":"Cardiovasc Diabetol"},{"key":"ref57","article-title":"Risk of cardiovascular events in patients with polycystic ovary syndrome","volume":"70","author":"Iftikhar S","year":"2012","unstructured":"Iftikhar S, Collazo-Clavell ML, Roger VL, et al.. Risk of cardiovascular events in patients with polycystic ovary syndrome. Neth J Med. 2012, 70:74-80.","journal-title":"Neth J Med"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2724","article-title":"Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society","volume":"95","author":"Wild RA","year":"2010","unstructured":"Wild RA, Carmina E, Diamanti-Kandarakis E, et al.. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010, 95:2038-49. 10.1210\/jc.2009-2724","journal-title":"J Clin Endocrinol Metab"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18553","article-title":"Investigating fetuin-A and paraoxonase-1 activity as markers in polycystic ovary syndrome based on body mass index: a prospective case-control study","volume":"13","author":"Gurbuz T","year":"2021","unstructured":"Gurbuz T, Alanya Tosun S, Cebi A, Gokmen O, Usta M. Investigating fetuin-A and paraoxonase-1 activity as markers in polycystic ovary syndrome based on body mass index: a prospective case-control study. Cureus. 2021, 13:e18553. 10.7759\/cureus.18553","journal-title":"Cureus"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.57","article-title":"Polycystic ovary syndrome","volume":"2","author":"Azziz R","year":"2016","unstructured":"Azziz R, Carmina E, Chen Z, et al.. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016, 2:16057. 10.1038\/nrdp.2016.57","journal-title":"Nat Rev Dis Primers"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0628","article-title":"Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span","volume":"90","author":"Azziz R","year":"2005","unstructured":"Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab. 2005, 90:4650-8. 10.1210\/jc.2005-0628","journal-title":"J Clin Endocrinol Metab"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dey256","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"33","author":"Teede HJ","year":"2018","unstructured":"Teede HJ, Misso ML, Costello MF, et al.. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018, 33:1602-18. 10.1093\/humrep\/dey256","journal-title":"Hum Reprod"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.7.6692","article-title":"Effects of resistance training and endurance training on insulin sensitivity in nonobese, young women: a controlled randomized trial","volume":"85","author":"Poehlman ET","year":"2000","unstructured":"Poehlman ET, Dvorak RV, DeNino WF, Brochu M, Ades PA. Effects of resistance training and endurance training on insulin sensitivity in nonobese, young women: a controlled randomized trial. J Clin Endocrinol Metab. 2000, 85:2463-8. 10.1210\/jcem.85.7.6692","journal-title":"J Clin Endocrinol Metab"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-153-3-201008030-00005","article-title":"Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial","volume":"153","author":"Foster GD","year":"2010","unstructured":"Foster GD, Wyatt HR, Hill JO, et al.. Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. Ann Intern Med. 2010, 153:147-57. 10.7326\/0003-4819-153-3-201008030-00005","journal-title":"Ann Intern Med"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2008.09.018","article-title":"Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society","volume":"92","author":"Moran LJ","year":"2009","unstructured":"Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril. 2009, 92:1966-82. 10.1016\/j.fertnstert.2008.09.018","journal-title":"Fertil Steril"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-0618","article-title":"Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome","volume":"30","author":"Meyer C","year":"2007","unstructured":"Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care. 2007, 30:471-8. 10.2337\/dc06-0618","journal-title":"Diabetes Care"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deq301","article-title":"The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of observational studies","volume":"26","author":"Halperin IJ","year":"2011","unstructured":"Halperin IJ, Kumar SS, Stroup DF, Laredo SE. The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of observational studies. Hum Reprod. 2011, 26:191-201. 10.1093\/humrep\/deq301","journal-title":"Hum Reprod"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)58321-6","article-title":"Plasma lipids and desogestrel and ethinyl estradiol: a meta-analysis","volume":"65","author":"Lobo RA","year":"1996","unstructured":"Lobo RA, Skinner JB, Lippman JS, Cirillo SJ. Plasma lipids and desogestrel and ethinyl estradiol: a meta-analysis. Fertil Steril. 1996, 65:1100-9. 10.1016\/S0015-0282(16)58321-6","journal-title":"Fertil Steril"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608293350902","article-title":"Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome","volume":"335","author":"Nestler JE","year":"1996","unstructured":"Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 1996, 335:617-23. 10.1056\/NEJM199608293350902","journal-title":"N Engl J Med"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031780","article-title":"Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study","volume":"89","author":"Ganie MA","year":"2004","unstructured":"Ganie MA, Khurana ML, Eunice M, Gupta N, Gulati M, Dwivedi SN, Ammini AC. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J Clin Endocrinol Metab. 2004, 89:2756-62. 10.1210\/jc.2003-031780","journal-title":"J Clin Endocrinol Metab"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2006.10.013","article-title":"Treatment of polycystic ovary syndrome with spironolactone plus licorice","volume":"131","author":"Armanini D","year":"2007","unstructured":"Armanini D, Castello R, Scaroni C, et al.. Treatment of polycystic ovary syndrome with spironolactone plus licorice. Eur J Obstet Gynecol Reprod Biol. 2007, 131:61-7. 10.1016\/j.ejogrb.2006.10.013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031281","article-title":"Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity","volume":"89","author":"Ib\u00e1\u00f1ez L","year":"2004","unstructured":"Ib\u00e1\u00f1ez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab. 2004, 89:1592-7. 10.1210\/jc.2003-031281","journal-title":"J Clin Endocrinol Metab"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2250","article-title":"Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study","volume":"91","author":"Gambineri A","year":"2006","unstructured":"Gambineri A, Patton L, Vaccina A, et al.. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab. 2006, 91:3970-80. 10.1210\/jc.2005-2250","journal-title":"J Clin Endocrinol Metab"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1097\/01.OGX.0000109523.25076.E2","article-title":"Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls","volume":"59","author":"Legro RS","year":"2004","unstructured":"Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv. 2004, 59:141-54. 10.1097\/01.OGX.0000109523.25076.E2","journal-title":"Obstet Gynecol Surv"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0237","article-title":"Diagnosis and follow-up of type 2 diabetes in women with PCOS: a role for OGTT?","volume":"179","author":"Andersen M","year":"2018","unstructured":"Andersen M, Glintborg D. Diagnosis and follow-up of type 2 diabetes in women with PCOS: a role for OGTT?. Eur J Endocrinol. 2018, 179:D1-D14. 10.1530\/EJE-18-0237","journal-title":"Eur J Endocrinol"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-S067","article-title":"Diagnosis and classification of diabetes mellitus","volume":"36","author":"American Diabetes Association","year":"2013","unstructured":"American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013, 36:67-74. 10.2337\/dc13-S067","journal-title":"Diabetes Care"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-1-200207020-00009","article-title":"Metformin: an update","volume":"137","author":"Kirpichnikov D","year":"2002","unstructured":"Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002, 137:25-33. 10.7326\/0003-4819-137-1-200207020-00009","journal-title":"Ann Intern Med"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021688","article-title":"Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome","volume":"88","author":"Morin-Papunen L","year":"2003","unstructured":"Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003, 88:4649-54. 10.1210\/jc.2002-021688","journal-title":"J Clin Endocrinol Metab"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7421.951","article-title":"Metformin in polycystic ovary syndrome: systematic review and meta-analysis","volume":"327","author":"Lord JM","year":"2003","unstructured":"Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003, 327:951-3. 10.1136\/bmj.327.7421.951","journal-title":"BMJ"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13493-9","article-title":"Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome","volume":"361","author":"Harborne L","year":"2003","unstructured":"Harborne L, Fleming R, Lyall H, Norman J, Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet. 2003, 361:1894-901. 10.1016\/S0140-6736(03)13493-9","journal-title":"Lancet"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet0511","article-title":"Is metformin the treatment of choice for anovulation in polycystic ovary syndrome?","volume":"3","author":"Balen AH","year":"2007","unstructured":"Balen AH. Is metformin the treatment of choice for anovulation in polycystic ovary syndrome?. Nat Clin Pract Endocrinol Metab. 2007, 3:440-1. 10.1038\/ncpendmet0511","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005552.pub3","article-title":"Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome","volume":"8","author":"Fraison E","year":"2020","unstructured":"Fraison E, Kostova E, Moran LJ, Bilal S, Ee CC, Venetis C, Costello MF. Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome. Cochrane Database Syst Rev. 2020, 8:CD005552. 10.1002\/14651858.CD005552.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063971","article-title":"Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome","volume":"356","author":"Legro RS","year":"2007","unstructured":"Legro RS, Barnhart HX, Schlaff WD, et al.. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007, 356:551-66. 10.1056\/NEJMoa063971","journal-title":"N Engl J Med"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0176","article-title":"Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome","volume":"90","author":"Jayagopal V","year":"2005","unstructured":"Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL. Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J Clin Endocrinol Metab. 2005, 90:729-33. 10.1210\/jc.2004-0176","journal-title":"J Clin Endocrinol Metab"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02693.x","article-title":"Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome","volume":"66","author":"Diamanti-Kandarakis E","year":"2007","unstructured":"Diamanti-Kandarakis E, Katsikis I, Piperi C, Alexandraki K, Panidis D. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol. 2007, 66:103-9. 10.1111\/j.1365-2265.2006.02693.x","journal-title":"Clin Endocrinol"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/den454","article-title":"An RCT of metformin versus orlistat for the management of obese anovulatory women","volume":"24","author":"Metwally M","year":"2009","unstructured":"Metwally M, Amer S, Li TC, Ledger WL. An RCT of metformin versus orlistat for the management of obese anovulatory women. Hum Reprod. 2009, 24:966-75. 10.1093\/humrep\/den454","journal-title":"Hum Reprod"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1007\/BF03401383","article-title":"A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome","volume":"14","author":"Jensterle M","year":"2015","unstructured":"Jensterle M, Kravos NA, Pfeifer M, Kocjan T, Janez A. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Hormones. 2015, 14:81-90. 10.1007\/BF03401383","journal-title":"Hormones"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1490","article-title":"The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery","volume":"90","author":"Escobar-Morreale HF","year":"2005","unstructured":"Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, Sancho J, San Mill\u00e1n JL. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab. 2005, 90:6364-9. 10.1210\/jc.2005-1490","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/96404-cardio-metabolic-disease-and-polycystic-ovarian-syndrome-pcos-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:40:15Z","timestamp":1707507615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/96404-cardio-metabolic-disease-and-polycystic-ovarian-syndrome-pcos-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":88,"URL":"https:\/\/doi.org\/10.7759\/cureus.25076","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,17]]}}}